Abbott Laboratories has inked a deal with Surmodics Inc. to collaboratively develop, trial and seek EU and U.S. approval for the Surveil drug coated balloon (DCB) in treatment of superficial femoral artery. Abbott will obtain exclusive global commercialization rights for Surveil under the agreement, which includes a $25 million initial payment to Surmodics and $67 million in potential milestone payments. Surveil is being assessed in a U.S. pivotal, randomized trial, TRANSCEND. Read More
